TITLE

Profile of soluble cytokine receptors in Crohn's disease

AUTHOR(S)
Gustot, T.; Lemmers, A.; Louis, E.; Nicaise, C.; Quertinmont, E.; Belaiche, J.; Roland, S.; Van Gossum, A.; Devière, J.; Franchimont, D.
PUB. DATE
April 2005
SOURCE
Gut;Apr2005, Vol. 54 Issue 4, p488
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Soluble cytokine receptors (sCRs) modulate the in vivo activity of cytokines. Deficient sCR production could participate in the pathogenesis and course of Crohn's disease (CD). The aim of the study was to examine the profile of sCRs in CD patients and their modulation by infliximab and corticosteroids. Methods: We prospectively examined active CD patients (aCD) treated with either infliximab (n =21) or corticosteroids (n = 9), CD patients in clinical remission (rCD, n = 20), ulcerative colitis patients (UC, = 24), and healthy subjects (HS, n = 15). Cultures of colonic biopsies were also examined from CD inflamed (n = 8), CD non-inflamed (n = 7), and healthy mucosa (n = 8). Levels of tumour necrosis factor α (TNF-α), soluble TNF receptor I (sTNFRI), soluble TNF receptor II (sTNFRII), interleukin 1β (IL-1β), soluble IL-1 receptor II (slL-1RII), soluble IL-1 receptor (slL-6R), IL-6, soluble 1L-6 receptor (sIL-6R), and sgp130 were measured using ELISA. Results: Higher levels of sTNFRI (p<0.05, p<0.01), sTNFRII (p<0.01, p<0.01), slL-1Rh (p<0.05, NS), IL-6 (p<0.01, p<0.01), and sIL-6R (p<0.05, NS) were observed in aCD compared with rCD and HS. Interestingly, sIL-1RII (p<0.05, p<0.01) and sgp130 (p<0.01, p<0.01) were profoundly decreased in aCD compared with rCD and HS, and were negatively correlated with CRP. Deficient production of sIL- 1RII was specific to CD (not observed in ulcerative colitis), and was further confirmed at the mucosal level. Infliximab decreased sINFRII at one and four weeks (p<0.05) and enhanced sIL-6R levels at one week (p<0.05). Corticosteroids increased sIL-1 Ru levels at one week (p<0.05). Conclusion: CD is associated with dysregulated production of sCRs. Deficiency in sIL-1RII and sgp 130 may be essential to CD pathogenesis. Their replacement through the use of fusion proteins could represent future alternative therapeutic strategies for CD.
ACCESSION #
16556652

 

Related Articles

  • Entocort.  // Royal Society of Medicine: Medicines;2002, p227 

    The article presents information on Entocort, a proprietary, prescription-only preparation of the budesonide. It can be used for the induction of remission in mild to moderate Crohn's disease affecting the ileum and ascending colon, in the form of capsules, or for ulcerative colitis in the form...

  • Cytokine and Anti-cytokine Therapies for Inflammatory Bowel Disease. Ogata, Haruhiko; Hibi, Toshifumi // Current Pharmaceutical Design;May2003, Vol. 9 Issue 14, p1107 

    Although the pathogenesis of inflammatory bowel disease (IBD) remains elusive, it appears that there is chronic activation of the immune and inflammatory cascade in genetically susceptible individuals. Current disease management guidelines have therefore focused on the use of anti-inflammatory...

  • Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. de Mattos, Bruno Rafael Ramos; Garcia, Maellin Pereira Gracindo; Nogueira, Julia Bier; Paiatto, Lisiery Negrini; Albuquerque, Cassia Galdino; Souza, Caique Lopes; Fernandes, Luís Gustavo Romani; Tamashiro, Wirla Maria da Silva Cunha; Simioni, Patricia Ucelli // Mediators of Inflammation;8/3/2015, Vol. 2015, p1 

    Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn’s disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due...

  • Corticosteroids.  // Reactions Weekly;1/12/2008, Issue 1184, p14 

    The article describes the case of four patients with inflammatory bowel disease and who developed steroid allergy during treatment with corticosteroids. Three patients, a 40-year old man with Crohn's disease, a 53-year old woman and a 39-year old man both with ulcerative colitis, developed...

  • The Relationship Between Heritability and Smoking Habits in Crohn's Disease. Brignola, Corrado; Belloli, Clarissa; Ardizzone, Sandro; Astegiano, Marco; Cottone, Mario; Trallori, Giacomo // American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3171 

    OBJECTIVE: In Crohn's disease (CD), the relationship between genetic predisposition and smoking has not been well defined. The aim of this study was to compare the smoking habits at the time of the diagnosis of CD patients having familial occurrence of inflammatory bowel disease (IBD) with those...

  • REGIONAL ENTERITIS. Berger, Samuel S. // American Journal of Gastroenterology;Jul1956, Vol. 26 Issue 1, p81 

    Presents a case of a patient with regional enteritis. Persistence of abdominal pains suffered by the patient; Examination of the abdomen of the patient; Pathology of the regional enteritis.

  • Pneumatosis Cystoides Intestinalis with Free Intraperitoneal Air: A Case Report. Hwang, Joanna; Reddy, V. Sreenath; Sharp, Kenneth W. // American Surgeon; 

    Pneumatosis cystoides intestinalis (PCI) is a rare disorder of the medical management and clinical outcome of which largely depend on the severity of its clinical manifestation. A limited number of cases have been reported in the literature although it is suggested that the true incidence of...

  • Anastomotic Configuration and Mucosal 5-Aminosalicylic Acid (5-ASA) Concentrations in Patients With Crohn's Disease: A GISC Study. Frieri, Giuseppe; Pimpo, M. T.; Palumbo, G.; Tonelli, F.; Annese, V.; Sturniolo, G. C.; Andreoli, A.; Comberlato, M.; Corrao, G.; Caprilli, R. // American Journal of Gastroenterology;Jun2000, Vol. 95 Issue 6, p1486 

    OBJECTIVE: Recurrence of Crohn's disease quite inevitably occurs after resection of distal small bowel and proximal colon, involving the neoterminal ileum close to the anastomosis. Oral 5-aminosalicylic acid (5-ASA) administered soon after surgery delays recurrence and reduces its severity. We...

  • Portal Vein Gas in a Patient with Crohn's Colitis. Pappas, Dean; Romeau, Jose; Tarkin, Neil; Dave, Pradyuman B.; Messer, Julio; Maklansky, Daniel // American Journal of Gastroenterology;Sep1984, Vol. 79 Issue 9, p728 

    Presents a case report of hepatic portal venous gas in a patient with Crohn's disease. Medical history; Characteristics of hepatic portal venous gas; Etiologies of hepatic portal venous gas.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics